… coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative
agent of the coronavirus … Here I review the development of vaccines against SARS-CoV-2. …

… low doses of the Ad26.COV2.S vaccine protected rhesus macaques against SARSCoV-2
challenge, although higher vaccine doses … as compared with the lower respiratory tract. Both …

… of pseudotyped SARS-CoV-2 … by SARS-CoV-2 infection by using peripheral blood mononuclear
cells (PBMCs) from Donor 3 in two independent sorting strategies to isolate SARS-CoV-2…

Importance There is no specific antiviral therapy recommended for coronavirus disease 2019
(COVID-19). In vitro studies indicate that the antiviral effect of chloroquine diphosphate (CQ…

… A low dose intranasal challenge of the same SARS-CoV-2 virus (5 × 10 2 pfu) appeared to
result in infection of only one ferret which shed detectable viral RNA in the upper respiratory …

… using a lower infectious dose, we … SARS-CoV-2 transmission dynamics is important for
designing appropriate strategies for a more effective response to emerging variants of SARS-CoV…

… Understanding the pathogenesis of the SARS-CoV-2 infection is key to developing …
SARS-CoV-2 intranasal infection in ferrets and hamsters with low doses of low-passage SARS-CoV-…

Background The effectiveness and sustainability of current public health interventions designed
to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission …

… coronavirus 2 (SARS-CoV-2) … SARS-CoV-2 genomic diversity, the National Institute of
Allergy and Infectious Diseases within the National Institutes of Health established the SARS-CoV-…

… ( 23 ) By using the dose-response model developed … dose (d) of SARS-CoV for cases in
Block E from the attack rate (p(d)). The dose estimated on the above assumption might be lower …